Allele frequency differences of cytochrome P450 polymorphisms in a sample of New Zealand Maori

New Zealand Medical Journal

Volumn 121, Issue 1272, 2008, Pages

  Lea, Rod A ^a,c   Roberts, Rebecca L ^b   Green, Michael R ^a   Kennedy, Martin A ^b   Chambers, Geoffrey K ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DNA; NEUROLEPTIC AGENT; NICOTINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SULFONYLUREA DERIVATIVE; DRUG;

ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG METABOLISM; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAORI; NEW ZEALAND; PHARMACOGENETICS; PREVALENCE; VOLUNTEER; ABORIGINE; ALLELE; COMPARATIVE STUDY; GENETIC DATABASE; GENETICS; METABOLISM; METHODOLOGY; POPULATION GENETICS; STATISTICS;

ALLELES; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, GENETIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETICS, POPULATION; HUMANS; NEW ZEALAND; OCEANIC ANCESTRY GROUP; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, GENETIC;

EID: 42949083779     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Lea RA and Chambers GK. Pharmacogenomics in Admixed Polynesian Population. In: Suarez-Kurtz G (ed). Pharmacogenomics in Admixed Populations. Austin, TX: Landes Bioscience; 2007, p165-79.
2. Wanwimolruk S, Pratt EL, Denton JR, et al. Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori population. Pharmacogenetics. 1995;5(4):193-8.
3. Lea R, Benowitz N, Green M, et al. Ethnic differences in nicotine metabolic rate among New Zealanders. N Z Med J. 2006; 118(1227). http://www.nzma.org.nz/journal/118-1227/1773
4. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996;6(4):341-9.
5. Roberts RL, Kennedy MA. Rapid detection of common cytochrome P450 2D6 alleles in Caucasians. Clin Chim Acta. 2006;366(1-2):348-51.
6. Goldstein JA, Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol. 1996;272:210-8.
7. Suarez-Kurtz G. Pharmacogenomics in admixed populations. Trends Pharmacol Sci. 2005;26(4):196-201. [Review]
8. Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′hydroxylase(CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics. 1999;9(5):539-49.
9. Griese EU, Ilett KF, Kitteringham NR, et al. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia. Pharmacogenetics. 2001;11(1):69-76.
10. Schoedel KA, Hoffman EB, Rao Y, et al. Ethnic variation in CYP2A6 and association of genetically slow metabolism and smoking in adult Caucasians. Pharmacogenetics. 2004;14:615-26.
11. Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther. 2005;77(3):145-58.